Share this Page:
A paper published in the European Journal of Cancer earlier this month reports on the experience of six French hospitals with stereotactic radiotherapy (SRT) for metastatic renal cell carcinoma (RCC) between 2008 and 2015 .
This retrospective study showed a 12-month local control rate of metastases of 82.9%. Twenty-five percent of patients with oligometastatic disease (with a small number of metastases) did not have a relapse of their disease.
The study concluded that SRT is both safe and effective in managing RCC patients with oligometastatic and oligoprogressive disease.